Imfinzi is the brand name for durvalumab, a PD-L1–blocking monoclonal antibody developed by MedImmune/AstraZeneca. Like most biologics, it’s protected by a portfolio of patents and regulatory exclusivities, including:
- Composition-of-matter patents on durvalumab itself
- Patents on therapeutic uses and treatment combinations (e.g., with chemotherapy, in specific cancers)
- Patents on formulations, manufacturing methods, and related antibody variants
- Regulatory data exclusivity (e.g., biologics data exclusivity in the U.S.)
Patent expiry and status are country-specific and can be complex due to multiple patent families and possible term extensions. In the U.S., exclusivity for a biologic also includes regulatory data exclusivity (12 years for new biologics, which can delay generic/biosimilar competition even after patents expire).
If you want precise current status for a specific country, I can help you outline how to check (or summarize) the relevant patent families. I can’t fetch live databases here unless you’d like me to guide you step-by-step, but in short:
- Useful databases: Google Patents, USPTO Patent Center (U.S.), Espacenet (Europe), WIPO Patentscope (PCT).
- Search ideas: “durvalumab” or “Imfinzi” with assignee “AstraZeneca” or “MedImmune,” plus terms like “composition,” “uses,” “method of treatment,” “formulation,” and country filters.
- Look for the earliest priority dates, family members, and any term adjustments or extensions.
- Remember to consider both patent protection and regulatory data exclusivity when assessing freedom-to-operate.
Would you like me to focus on a specific country (e.g., U.S., EU, UK, or another) and summarize the currently active patent families and approximate expiry windows there? If you tell me the jurisdiction, I’ll lay out the likely patents and how to verify them.